All Stories

AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients

The addition of Imfinzi to standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy helped patients live longer without their disease coming back, AstraZeneca said on Friday.

May 9, 2025 - 15:18
 0
AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients
The addition of Imfinzi to standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy helped patients live longer without their disease coming back, AstraZeneca said on Friday.
Read More

Tags:

Previous Article

Roche pledges nearly $300M to establish new Vabysmo production plant in China

Next Article

Shopify Sees Second-Quarter Revenue Above Market Estimates

Related Posts

Dynavax-sponsored survey shows lack of awareness of hepatitis B risks, vaccine options

Dynavax-sponsored survey shows lack of awareness of hep...

May 1, 2025  0

Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch

Gilead, 'closely attuned to' potential US policy shifts...

Apr 25, 2025  0

2 years after leaving PhRMA, AstraZeneca opts back in

2 years after leaving PhRMA, AstraZeneca opts back in

Apr 22, 2025  0